The Claim
In Japanese adults with type 2 diabetes, administration of linagliptin or liraglutide does not impair glucose recovery following induced hypoglycemia, as measured by glucose infusion rates and time to restoration of normoglycemia after cessation of insulin infusion.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In Japanese adults with type 2 diabetes, linagliptin and liraglutide do not slow the return of blood glucose to normal levels after a hypoglycemic episode induced by insulin infusion.
See the scientific wording
In Japanese adults with type 2 diabetes, neither linagliptin nor liraglutide impairs glucose recovery after induced hypoglycemia, as measured by glucose infusion rates and time to normoglycemia following insulin infusion cessation.
When blood sugar drops, the pancreas releases glucagon, which tells the liver to release stored sugar into the blood. This process works normally even when linagliptin or liraglutide are present, so blood sugar returns to normal without delay.
What the research says
1 studyThe study found that even after taking these diabetes drugs, the body still released the right hormone (glucagon) to raise blood sugar when it got too low — meaning these drugs don’t stop the body from fixing low blood sugar on its own.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.